FindTrial
Sign In

Associations of CYP3A and ABCB1 Polymorphisms with Pharmacokinetics of Cyclosporine A in Early Renal Recipients after Transplantation

Associations of CYP3A and ABCB1 Polymorphisms with Pharmacokinetics of Cyclosporine A in Early Renal Recipients after Transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-12002181
Enrollment
Unknown
Registered
2012-05-17
Start date
2011-03-12
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplantation

Interventions

1:after renal transplantation

Sponsors

Institute of Clinical Pharmacology, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Han Chinese; more than 18 or less than 60 years; having no a history of renal transplantation or multiple organ transplantation; ABO blood type compatibility; PRA negative

Exclusion criteria

Exclusion criteria: taking other medications influencing PK of CsA except calcium-channel blocker Diltiazem Hydrochloride (Hexinshuang, Tanabe Seiyaku, Tianjin, China); having a history of hepatitis B, hepatitis C or HIV; or being patients whose electronic medical records cannot be obtained.

Design outcomes

Primary

MeasureTime frame
Blood Drug Concentratio;—

Countries

China

Contacts

Public ContactHonghao Zhou
hhzhou2003@163.com+86 0731 84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026